Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients With Chronic Inducible Urticaria (Part B)
Conditions
Interventions
GTX-B001
Normal Saline
Locations
2
Germany
Charité Research Organization gmbh
Berlin, Germany
Fraunhofer Institute For Translational Medicine And Pharmacology
Berlin, Germany
Start Date
October 6, 2025
Primary Completion Date
August 1, 2027
Completion Date
August 1, 2027
Last Updated
January 30, 2026
NCT06342713
NCT06014515
NCT06544018
NCT07266402
NCT07364149
NCT07219940
Lead Sponsor
Granular Therapeutics Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions